The present invention relates to medical stents and related methods. More specifically, the invention relates to medical stents having one end section which is softer than a section at the other end of the stent.
Fluid sometimes needs to be drained from a body. For example, urine formed in one or both kidneys might need to be drained into the bladder. One way to accomplish such drainage is to use a medical device that conveys the fluid (e.g., urine) through a lumen. Such devices include stents and catheters. Existing stents can be uncomfortable for the patient, especially when they reside in the ureter between the kidney and the bladder, or can be difficult for a medical professional to place in a patient.
The present invention provides medical stents for facilitating drainage of fluid and methods for placing such stents. For example, such stents can be placed in a ureter to facilitate drainage of fluid from a patient's kidney to a patient's bladder. Generally, stents according to the invention have a “softer” end and a “harder” end. The harder end generally resides in the patient's kidney while the softer end generally resides in the patient's bladder. The harder end transitions to the softer end in a transition section produced by a co-extrusion process where deposition of a first material is gradually ceased and deposition of a second is gradually increased. The harder end is suited to retain the stent in the patient's kidney and/or facilitate placement in a patient while the softer end is suited to increase patient comfort and/or, to a degree, retain the stent in the patient's bladder. Such stents also are useful in other situations such as biliary drainage or, generally, where one body structure is drained to another body structure.
In one embodiment, a medical stent includes a single-piece, extruded stent body which does not substantially soften when exposed to a temperature of a human body. At least a portion of the stent body can be sized for placement in a ureter, and at least a section of the stent body can define holes therethrough. The stent body itself includes a first section, a second section, and a third section defining a lumen and located between the first and second sections. The first section includes a first material having a first durometer value while the second section includes a second material having a second durometer value. The second durometer value is greater than the first durometer value. The third section includes a co-extrusion of the first and second materials that is disposed between the first coil and the second coil. The first section defines a lumen and includes a first coil completing at least one revolution, and the second section defines a lumen and includes a second coil completing at least one revolution. An outer surface of the third section smoothly transitions to outer surfaces of the first and second sections immediately proximate the third section, and an inner diameter of the third section is substantially constant through the third section and on either side of the third section immediately proximate to the third section in the first and second sections.
The embodiment described above, or those described below, can have any of the following features. The first material can include ethylene vinyl acetate. The stent body can include a mark on an outer surface of the stent body. The stent body can include a radiopaque marking. The stent can have an outer diameter of about 4 French to about 9 French. The stent can have an inner diameter of about 0.38 inches. The stent can have a length of about 10 cm to about 30 cm as measured between the coils. The stent can include a hydrophilic coating. The first material can have a durometer value of about 70 to about 90 on a Shore A scale. The second material can have a durometer value of about 80 to about 95 on a Shore A scale. At least one of the coils can be asymmetric. An end of at least one of the first section and the second section can be tapered. A cross-section of the lumen in at least one of the first, second, and third sections can be circular. A cross-section of at least one of the first, second, and third sections can be circular. At least one of the first, second, and third section can include a radiopaque material.
In another embodiment, a medical stent includes a single-piece, extruded stent body which does not substantially soften when exposed to a temperature of a human body. At least a portion of the stent body can be sized for placement in a ureter, and at least a section of the stent body can define holes therethrough. The stent body itself includes a first section, a second section, and a third section defining a lumen and located between the first and second sections. The first section defines a lumen and includes a first coil completing at least one revolution, and the second section defines a lumen and includes a second coil completing at least one revolution. The first section includes a first material, and the second section includes a second material. The first coil has a first retention strength, and the second coil has a second retention strength. The second retention strength is greater than the first retention strength. The third section includes a co-extrusion of the first and second materials that is disposed between the first coil and the second coil. An outer surface of the third section smoothly transitions to outer surfaces of the first and second sections immediately proximate the third section. An inner diameter of the third section is substantially constant through the third section and on either side of the third section immediately proximate to the third section in the first and second sections.
In another aspect of the invention, a method for placing a medical stent includes inserting a medial stent, including any of the stents described above or below with any of the features described above or below, into a ureter.
In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating principles of the invention.
The present invention provides medical stents for facilitating drainage of fluid and methods for placing such stents. For example, such stents are placed in a ureter to facilitate drainage of fluid from a patient's kidney to a patient's bladder. Generally, stents according to the invention have a “softer” end and a “harder” end. The harder end generally resides in the patient's kidney while the softer end generally resides in the patient's bladder. The harder end transitions to the softer end in a transition section produced by a co-extrusion process where deposition of a first material is gradually ceased and deposition of a second is gradually increased. As used herein, the terms “hard” and “soft,” and various grammatical forms thereof, are general terms meant to generally refer to a difference in properties, including, but not limited to, a difference in the durometer value of all or some of the material(s) used to construct a stent (for example, a higher durometer value of one material used in constructing a section of a stent (even if other materials are also used to construct that same section of stent) can mean “hard” and a lower durometer value of one material used in constructing another section of a stent (even if other materials are also used to construct that same section of stent) can mean “soft”), a difference in the retention strengths of the coils on either end of a stent (for example, a higher retention strength can mean “hard” and a lower retention strength can mean “soft”), a difference in stiffness (for example, a more stiff material/section of stent can be “hard” and a less stiff material/section of stent can be “soft”), or other differences between material(s) used to construct a stent or between sections of a stent that those skilled in the art would consider “hard” and/or “soft.”
On the one hand, some ureteral stents that are in use are made from a higher durometer material to facilitate placement and retention in the body. However, these firmer stents may contribute to some patient discomfort issues. On the other hand, some ureteral stents that are in use are made from a lower durometer material in an effort to enhance patient comfort. However, these softer stents may be difficult to place and may migrate once placed in the patient's body.
In contrast, stents according to the invention have a harder end at one end and a softer end at the other end. This construction is desirable because the harder end is suited for placing the stent in the patient's kidney and/or to retain the stent in the patient's kidney while the softer end is suited to increase patient comfort and/or, to a degree, retain the stent in the patient's bladder. Accordingly, stents according to the invention are designed to incorporate multiple desirable features into a single stent.
Referring to
The third section 22 is formed from a coextrusion of the material(s) from which the first section 24 is made and the material(s) from which the second section 20 is made. As shown in
The stent 10 is a single piece and is sized to fit within a ureter. For example, two types of ethylene vinyl acetate (“EVA”) can be extruded to form the stent. In a continuous process, the first section 24 is formed from one type of EVA; a transition section (i.e., the third section 22), then, is formed by gradually ceasing the deposition of the first type of EVA and gradually increasing the deposition of a second type of EVA; and the other end of the stent, the second section 20, is formed from the second type of EVA after the first type of EVA has ceased being extruded. Each type of EVA has a different durometer value, with the first type of EVA having a durometer value that is less than the durometer value of the second type of EVA. The two materials in the third section 22 are separate, are distinct, and are associated with each other in an irregular configuration. Additionally, other materials may be mixed with the first and/or second types of the EVA prior to extrusion. For example, radiopaque materials, such as bismuth subcarbonate, and/or colorants can be added. The addition can occur at the site of manufacture or a supplier can supply the EVA already compounded with the radiopaque material alone or with the colorant alone or with both the radiopaque material and the colorant. Even if these materials are mixed, the fact that one EVA type has a durometer value less than the second EVA type can mean that the section of the stent formed from the first type of EVA is “softer” than the section of the stent formed from the second type of EVA.
After extrusion, the curled portions are formed. For example, the extrusion can be placed on a mandrel, shaped in a particular form, and the extrusion can be formed into a desired shape by heating the extrusion while on the mandrel. Alternatively, the extrusion can be laid into a plate having a groove cut into it in the shape of the desired final product. The plate is heated from below (for example, with a heat lamp) to form the extrusion into a shape according to the configuration of the groove. Both coils can be formed at the same time using two adjacent plates, each with a groove for the coil at either end of the stent. The plates are heated at different temperatures, to the extent necessary, for example, if the two ends of the stent are made from different material(s), and can be heated for the same length of time. Additionally, after extrusion, holes can be bored into the stent by placing a nylon core inside the stent to prevent the stent from collapsing and drilling through the stent, for example, with a hollow sharpened bit.
In certain embodiments, the material(s) that make up the second section of the stent (the harder section of the stent) can extend at least half way down the shaft of the stent, and can extend even further, such that the transition section (e.g., the third section in
Interrupted layer extrusion techniques, gradient-type coextrusion techniques, or similar techniques can be used to produce the transition sections described above. Such extrusion techniques can be used instead of using joints or welds to bring together two ends of a stent, each end having a different physical property than the other end. Such joints or welds can fail during use of the stent and can be difficult to manufacture. Continuous material extrusion according to the invention enhances stent integrity while allowing for desired placement and drainage characteristics. Additionally, continuous extrusion products tend not to kink in the transition zone as might a stent with a butt-joint or a weld. In general, any type of thermoplastic polymer can be extruded such as a silicone, a polyurethane, or a polyolefin copolymer such as EVA. In general, in one embodiment of the invention, two types of EVA (at least one type of EVA can be mixed with a radiopaque material and at least one type of EVA can be mixed with a colorant) are extruded to form the stent. In a continuous process, one end of the stent is formed from one type of EVA (for example, the first section 24 in
In more detail and in one example of an extrusion technique as shown in
This system has at least three features. First, the entire system has no valves, and, specifically, the cross-head 68 has no moving parts such as valves. Second, extrusion can occur in a non-linear fashion, because the computer 58 and servo motors 55, 65 control the melt pumps 56, 66 on the basis of distance traveled. Thus, the melt pumps 56, 66 are “ramped up” or “ramped down” as necessary. Accordingly, a theoretically infinite gradient of material can be extruded by varying the pumping rates of the melt pumps 56, 66. And third, the process for combining the two EVA materials does not involve production of waste melted material as a byproduct of manufacture.
Through this machinery, in a continuous process, one end of the stent is formed from one type of EVA; a transition section, then, is formed by gradually ceasing the deposition of the first type of EVA and gradually increasing the deposition of a second type of EVA; and the other end of the stent is formed from the second type of EVA after the first type of EVA has ceased being extruded. Each type of EVA has a different durometer value. A radiopaque material and/or a colorant can be added to either of the EVA materials (the addition can occur at the site of manufacture or a supplier can supply the EVA already compounded with the radiopaque material, such as bismuth subcarbonate, alone or with the colorant alone or with both the radiopaque material and the colorant). The mixing of the two types of EVA in the transition section results in a section in which the two materials are separate, are distinct, and are associated with each other in an irregular configuration. After extrusion, the curled portions are formed. For example, the extrusion can be placed on a mandrel, shaped in a particular form, and the extrusion can be formed into a desired shape by heating the extrusion while on the mandrel. Alternatively, the extrusion can be laid into a plate having a groove cut into it in the shape of the desired final product. The plate is heated from below (for example, with a heat lamp) to form the extrusion into a shape according to the configuration of the groove. Both coils can be formed at the same time using two adjacent plates, each with a groove for the coil at either end of the stent. The plates are heated at different temperatures, to the extent necessary, for example, if the two ends of the stent are made from different material(s), and can be heated for the same length of time. Additionally, after extrusion, holes can be bored into the stent by placing a nylon core inside the stent to prevent the stent from collapsing and drilling through the stent, for example, with a hollow sharpened bit. The stent also can be covered in part or in its entirety with a lubricant. Useful coatings include those that are hydrophilic.
Various embodiments of medical stents according to the invention can have any of a variety of features. A dual durometer stent that incorporates a higher durometer value material (for example, firm EVA) for the renal coil and that gradually transitions into a lower durometer value material (for example, soft EVA) for the bladder coil is useful. For example, the “hard” material can be EVA having a durometer value of about 80 to about 95 on a Shore A scale, preferably about 87 to about 95 on a Shore A scale, and more preferably about 90 on a Shore A scale, and the “soft” material can be another type of EVA having a durometer value of about 70 to about 90 on a Shore A scale, preferably about 78 to about 90 on a Shore A scale, and more preferably about 86 on a Shore A scale. These values are examples of a more general principle, namely, having a stent with a harder end and a softer end. Other materials or EVA having a durometer value different than that described above can be useful. In some embodiments, the materials forming the stent, such as the two types of EVA, are mixed with other materials. For example, as described above, each type of EVA can be mixed with a radiopaque material, such as bismuth subcarbonate, or a colorant. The radiopaque material allows a medical professional to place the stent under the guidance of an x-ray device and fluoroscope or other similar device where the radiopaque material appears on a view screen because it blocks or reflects x-ray energy. The colorant also can be used as a visual cue to a medical professional about the location of the stent in the patient.
Another way to describe the two ends of the stent are by the coil retention strength of each coil of the stent. For example, such retention strengths can be used as a measure of the ability to resist migration within a patient, or, more broadly, as a measure of how “hard” or how “soft” the ends of the stent are. One way to determine retention strength is found in American Society for Testing and Materials (ASTM) Designation F 1828-97: Standard Specification for Ureteral Stents, approved Nov. 10, 1997, and published May, 1998, the disclosure of which is incorporated herein by reference. This specification covers single-use ureteral stents with retaining means at both ends, during short term use for drainage of urine from the kidney to the bladder. These stents typically have diameters of 3.7 French to 14.0 French, lengths of 8 cm to 30 cm, and are made of silicone, polyurethane, and other polymers. They are provided non-sterile for sterilization and sterile for single-use. It is noted that this ASTM standard excludes long-term, indwelling usage (over thirty days), use of ureteral stents for non-ureteral applications, and non-sterile stents. Nevertheless, even if stents according to the invention meet any of these exclusions, or do not otherwise fall under the scope of this ASTM standard, to the extent those skilled in the art understand it to be reasonable to use the coil retention strength test method described in this document, the test method can be used.
The retention strength test method (section 6.2 of the ASTM document) involves using a funnel block submerged in a water bath at approximately 37 degrees Celsius. The funnel block is a block of TEFLON or DERLIN defining a funnel. The funnel is two inches at its widest diameter and, in cross section, has walls that form an approximately 60 degree angle. The funnel narrows to a bore slightly larger than the specimen to be tested, and this bore is about 0.675 inches long. There must be clearance between the outside diameter of the test specimen and the inside diameter of the hole in the funnel block through which the specimen is pulled. For example, for stents of 3.7 to 8.5 French, a funnel bore should be 0.125 inches (3.16 mm) in diameter; for stents of 10.0 French, a funnel bore should be 0.159 inches (4.04 mm) in diameter; and for stent of 14.0 French, a funnel bore should be 0.210 inches (5.33 mm) in diameter. The test specimen is removed from its sterile packaging, and the retention means (for example, a coil at the end of the stent) of the specimen is straightened with an appropriate guidewire. The test specimen is soaked for at least thirty days and is cut to allow a straight portion of the stent to be inserted upwards through the funnel fixture into the grip of a tensile test machine without loading the retention mechanism of the stent to be tested. Prior to inserting the test specimen, the test specimen is submerged in the water bath for at least one minute to allow it to reach thermal equilibrium. If the material is significantly effected by moisture, the test specimen should be allowed to equilibrate for a minimum of 24 hours. The straight portion of the stent then is inserted through the bottom of the funnel and into the grip. If testing 30 days after opening the package, the retention means is not straightened prior to testing. Then, the specimen is pulled up through the funnel at 20 inches/minute. The maximum force required to pull the stent completely through the funnel is recorded.
Referring to
Some embodiments of stents according to the invention can have an outer diameter from about four to about nine French with lengths of from about ten to about thirty centimeters as measured between the coils.
The stent can have graduation marks and stent size imprinted on stent. For example, one marking pattern is shown in
In operation, the distal end of the stent 10 is inserted through the bladder 104 and ureter 102 into the kidney 100. For example, a medical professional inserts a guidewire (not shown) through the bladder 104, ureter 102 and kidney 100 of a patient. The stent 10 is placed over the guidewire, thereby uncurling the coils 12, 14 to the straightened position. The stent 10 slides along the guidewire, and the guidewire is sufficiently stiff to hold the coils 12, 14 in a straight configuration (e.g., the proximal coil in a straightened position 26,
The tapered tip on the second coil 14 (the renal coil) can facilitate inserting the stent through the passages of the patient's body. Additionally, a medical professional can use the suture 18 to reposition the stent (by pulling on it) when inserting the stent, and the medical professional can use the suture 18 to remove the stent from the patient. For example, the medical professional either leaves the suture inside the patient's body or leaves the end of the suture outside the body. When the stent 10 is to be removed, the medical professional pulls on the suture 18, removing the stent. However, the suture 18 does not have to be used to remove the stent 10.
When placed in a patient's body, stents according to the invention may soften slightly, as might many thermoplastic materials when exposed to elevated temperatures, for example, but without limitation, by about 30% or less, or about 20% or less, or about 10% or less, or about 5% or less. However, such softening is not substantial. Softening can be measured by methods known in the art. For example, the ASTM test method described herein may be adapted to determine if coils soften by determining if body temperature conditions cause a decrease in retention strength relative to room temperature conditions. However, other methods may be used.
An alternative method to straighten the coil 12 of the second section 20 is to produce relative movement between a straightening device (e.g., a sheath) and second section 20, such that the straightening device moves distally relative to the second section 20, thereby uncurling the coil 12 to a straightened position. Once at least some portion of the second section 20 is positioned within the kidney 100, the straightening device is removed. The second section 20 is constructed from a shape-memory material. Thus, once the straightening device is withdrawn, the coil 12 in the straightened position returns to its coiled shape. A similar re-coiling of the first coil 14 also occurs when the straightening device is withdrawn from that area of the stent 10. Other modes of inserting and/or straightening a device also are useful.
Variations, modifications, and other implementations of what is described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. Accordingly, the invention is to be defined not only by the preceding illustrative description.
This application is a continuation of U.S. patent application Ser. No. 10/765,382, filed Jan. 27, 2004, entitled “Medical Stent and Related Methods,” now U.S. Pat. No. 7,291,180, which is a continuation of U.S. patent application Ser. No. 10/032,712, filed Oct. 24, 2001, now U.S. Pat. No. 6,719,804, which claims priority to and the benefit of U.S. Patent Application No. 60/280,809, filed on Apr. 2, 2001, all of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
191775 | Parsons | Jun 1877 | A |
256590 | Pfarre | Apr 1882 | A |
386603 | Parsons | Jul 1888 | A |
559620 | Shearer | May 1896 | A |
1211928 | Fisher | Jan 1917 | A |
2257369 | Davis | Sep 1941 | A |
3087493 | Schossow | Apr 1963 | A |
3314430 | Alley et al. | Apr 1967 | A |
3359974 | Khalil | Dec 1967 | A |
3394705 | Abramson | Jul 1968 | A |
3437088 | Bielinski | Apr 1969 | A |
3485234 | Stevens | Dec 1969 | A |
3593713 | Bogoff et al. | Jul 1971 | A |
3612050 | Sheridan | Oct 1971 | A |
3633579 | Alley et al. | Jan 1972 | A |
3726281 | Norton et al. | Apr 1973 | A |
3746003 | Blake et al. | Jul 1973 | A |
3788326 | Jacobs | Jan 1974 | A |
3828767 | Spiroff | Aug 1974 | A |
3902492 | Greenhalgh | Sep 1975 | A |
3906954 | Baehr et al. | Sep 1975 | A |
3920023 | Dye et al. | Nov 1975 | A |
3995623 | Blake et al. | Dec 1976 | A |
4004588 | Alexander | Jan 1977 | A |
4037599 | Raulerson | Jul 1977 | A |
4065264 | Lewin | Dec 1977 | A |
4069814 | Clemens | Jan 1978 | A |
4096860 | McLaughlin | Jun 1978 | A |
4099528 | Sorenson et al. | Jul 1978 | A |
4100246 | Frisch | Jul 1978 | A |
4129129 | Amrine | Dec 1978 | A |
4134402 | Marhurkar | Jan 1979 | A |
4138288 | Lewin | Feb 1979 | A |
4138457 | Rudd et al. | Feb 1979 | A |
4144884 | Tersteegen et al. | Mar 1979 | A |
4149535 | Volder | Apr 1979 | A |
4168703 | Kenigsberg | Sep 1979 | A |
4173981 | Mortensen | Nov 1979 | A |
4180068 | Jacobsen et al. | Dec 1979 | A |
4182739 | Curtis | Jan 1980 | A |
4183961 | Curtis | Jan 1980 | A |
4202332 | Tersteegen et al. | May 1980 | A |
4203436 | Grimsrud | May 1980 | A |
4204541 | Kapitanov | May 1980 | A |
4212304 | Finney | Jul 1980 | A |
4217895 | Sagae et al. | Aug 1980 | A |
4223676 | Wuchinich et al. | Sep 1980 | A |
4236520 | Anderson | Dec 1980 | A |
4239042 | Asai | Dec 1980 | A |
4248234 | Assenza et al. | Feb 1981 | A |
4257416 | Prager | Mar 1981 | A |
4270535 | Bogue et al. | Jun 1981 | A |
4307723 | Finney | Dec 1981 | A |
4327722 | Groshong et al. | May 1982 | A |
4334327 | Lyman et al. | Jun 1982 | A |
4385631 | Uthmann | May 1983 | A |
4385635 | Ruiz | May 1983 | A |
4403983 | Edelman et al. | Sep 1983 | A |
4405313 | Sisley et al. | Sep 1983 | A |
4405314 | Cope | Sep 1983 | A |
4406656 | Hattler et al. | Sep 1983 | A |
4413989 | Schjeldahl et al. | Nov 1983 | A |
4419094 | Patel | Dec 1983 | A |
D272651 | Mahurkar | Feb 1984 | S |
4443333 | Mahurkar | Apr 1984 | A |
4451252 | Martin | May 1984 | A |
4456000 | Schjeldahl et al. | Jun 1984 | A |
4484585 | Baier | Nov 1984 | A |
4493696 | Uldall | Jan 1985 | A |
4504264 | Kelman | Mar 1985 | A |
RE31873 | Howes | Apr 1985 | E |
4531933 | Norton et al. | Jul 1985 | A |
4540402 | Aigner | Sep 1985 | A |
4543087 | Sommercorn et al. | Sep 1985 | A |
4553959 | Hickey et al. | Nov 1985 | A |
4559046 | Groshong et al. | Dec 1985 | A |
4563170 | Aigner | Jan 1986 | A |
4563181 | Wijayarathna et al. | Jan 1986 | A |
4568329 | Mahurkar | Feb 1986 | A |
4568338 | Todd | Feb 1986 | A |
4581012 | Brown et al. | Apr 1986 | A |
4583968 | Mahurkar | Apr 1986 | A |
4596548 | DeVries et al. | Jun 1986 | A |
4601697 | Mammolenti et al. | Jul 1986 | A |
4601701 | Mueller, Jr. | Jul 1986 | A |
4608993 | Albert | Sep 1986 | A |
4610657 | Densow | Sep 1986 | A |
4619643 | Bai | Oct 1986 | A |
4623327 | Marhurkar | Nov 1986 | A |
4626240 | Edelman et al. | Dec 1986 | A |
4641652 | Hutterer et al. | Feb 1987 | A |
4643711 | Bates | Feb 1987 | A |
4643716 | Drach | Feb 1987 | A |
4648865 | Aigner | Mar 1987 | A |
4655771 | Wallsten | Apr 1987 | A |
4661396 | Andorf et al. | Apr 1987 | A |
4662404 | LeVeen et al. | May 1987 | A |
4666426 | Aigner | May 1987 | A |
4671795 | Mulchin | Jun 1987 | A |
4675004 | Hadford et al. | Jun 1987 | A |
4682978 | Martin | Jul 1987 | A |
4687471 | Twardowski et al. | Aug 1987 | A |
4692141 | Marhurkar | Sep 1987 | A |
4694838 | Wijayarthna et al. | Sep 1987 | A |
4713049 | Carter | Dec 1987 | A |
4722725 | Sawyer et al. | Feb 1988 | A |
4732152 | Wallstën et al. | Mar 1988 | A |
4737146 | Amaki et al. | Apr 1988 | A |
4738667 | Galloway | Apr 1988 | A |
4739768 | Engelson | Apr 1988 | A |
4747840 | Ladika et al. | May 1988 | A |
4753640 | Nichols et al. | Jun 1988 | A |
4755176 | Patel | Jul 1988 | A |
4769005 | Ginsburg et al. | Sep 1988 | A |
4770652 | Marhurkar | Sep 1988 | A |
4772268 | Bates | Sep 1988 | A |
4773432 | Rydell | Sep 1988 | A |
4775371 | Mueller, Jr. | Oct 1988 | A |
4776841 | Catalano | Oct 1988 | A |
4787884 | Goldberg | Nov 1988 | A |
4790809 | Kuntz | Dec 1988 | A |
4790810 | Pugh, Jr. et al. | Dec 1988 | A |
4795439 | Guest | Jan 1989 | A |
4808155 | Marhurkar | Feb 1989 | A |
4809710 | Williamson | Mar 1989 | A |
4813429 | Eshel et al. | Mar 1989 | A |
4813925 | Anderson, Jr. et al. | Mar 1989 | A |
4820262 | Finney | Apr 1989 | A |
4822345 | Danforth | Apr 1989 | A |
4838881 | Bennett | Jun 1989 | A |
4842582 | Marhurkar | Jun 1989 | A |
4842590 | Tanabe et al. | Jun 1989 | A |
4846791 | Hattler et al. | Jul 1989 | A |
4846814 | Ruiz | Jul 1989 | A |
4863442 | DeMello et al. | Sep 1989 | A |
4874360 | Goldberg et al. | Oct 1989 | A |
4887996 | Bengmark | Dec 1989 | A |
4888146 | Dandeneau | Dec 1989 | A |
4894057 | Howes | Jan 1990 | A |
4895561 | Marhurkar | Jan 1990 | A |
4913683 | Gregory | Apr 1990 | A |
4931037 | Wetterman | Jun 1990 | A |
4950228 | Knapp, Jr. et al. | Aug 1990 | A |
4954126 | Wallsten | Sep 1990 | A |
4960409 | Catalano | Oct 1990 | A |
4960411 | Buchbinder | Oct 1990 | A |
4961809 | Martin | Oct 1990 | A |
4963129 | Rusch | Oct 1990 | A |
4973301 | Nissenkorn | Nov 1990 | A |
4976690 | Solar et al. | Dec 1990 | A |
4978341 | Niederhauser | Dec 1990 | A |
4981482 | Ichikawa | Jan 1991 | A |
4985022 | Fearnot et al. | Jan 1991 | A |
4986814 | Burney et al. | Jan 1991 | A |
4990133 | Solazzo | Feb 1991 | A |
4994071 | MacGregor | Feb 1991 | A |
4995863 | Nichols et al. | Feb 1991 | A |
4995865 | Gahara et al. | Feb 1991 | A |
4995868 | Brazier | Feb 1991 | A |
4998919 | Schnepp-Pesch et al. | Mar 1991 | A |
5004456 | Botterbusch et al. | Apr 1991 | A |
5009636 | Wortley et al. | Apr 1991 | A |
5013296 | Buckberg et al. | May 1991 | A |
5019102 | Hoene | May 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5029580 | Radford et al. | Jul 1991 | A |
5041083 | Tsuchida et al. | Aug 1991 | A |
5053004 | Markel et al. | Oct 1991 | A |
5053023 | Martin | Oct 1991 | A |
5057073 | Martin | Oct 1991 | A |
5061275 | Wallstén et al. | Oct 1991 | A |
5078720 | Burton et al. | Jan 1992 | A |
5085629 | Goldberg et al. | Feb 1992 | A |
5116309 | Coll | May 1992 | A |
5124127 | Jones et al. | Jun 1992 | A |
5129910 | Phan et al. | Jul 1992 | A |
5135487 | Morrill et al. | Aug 1992 | A |
5135599 | Martin et al. | Aug 1992 | A |
5141502 | Macaluso, Jr. | Aug 1992 | A |
5147370 | McNamara et al. | Sep 1992 | A |
5149330 | Brightbill | Sep 1992 | A |
5156592 | Martin et al. | Oct 1992 | A |
5156596 | Balbierz et al. | Oct 1992 | A |
5156857 | Wang et al. | Oct 1992 | A |
5160325 | Nichols et al. | Nov 1992 | A |
5167623 | Cianci et al. | Dec 1992 | A |
5171216 | Dasse et al. | Dec 1992 | A |
5176625 | Brisson | Jan 1993 | A |
5176626 | Soehendra | Jan 1993 | A |
5178803 | Tsuchida et al. | Jan 1993 | A |
5188593 | Martin | Feb 1993 | A |
5190520 | Fenton, Jr. et al. | Mar 1993 | A |
5195962 | Martin et al. | Mar 1993 | A |
5197951 | Marhurkar | Mar 1993 | A |
5207648 | Gross | May 1993 | A |
5209723 | Twardowski et al. | May 1993 | A |
5211627 | William | May 1993 | A |
5221253 | Coll | Jun 1993 | A |
5221255 | Marhurkar et al. | Jun 1993 | A |
5221256 | Marhurkar | Jun 1993 | A |
5222949 | Kaldany | Jun 1993 | A |
5224953 | Morgentalker | Jul 1993 | A |
5234663 | Jones et al. | Aug 1993 | A |
5240677 | Jones et al. | Aug 1993 | A |
5242395 | Maglinte | Sep 1993 | A |
5246445 | Yachia et al. | Sep 1993 | A |
5250038 | Melker et al. | Oct 1993 | A |
5261879 | Brill | Nov 1993 | A |
5269802 | Garber | Dec 1993 | A |
5275597 | Higgins et al. | Jan 1994 | A |
5279560 | Morrill et al. | Jan 1994 | A |
5282784 | Willard | Feb 1994 | A |
5290585 | Elton | Mar 1994 | A |
5292305 | Boudewijn et al. | Mar 1994 | A |
5292321 | Lee | Mar 1994 | A |
5295954 | Sachse | Mar 1994 | A |
5308322 | Tennican et al. | May 1994 | A |
5308342 | Sepetka et al. | May 1994 | A |
5318532 | Frassica | Jun 1994 | A |
5324274 | Martin | Jun 1994 | A |
5330449 | Prichard et al. | Jul 1994 | A |
5338311 | Marhurkar | Aug 1994 | A |
5342301 | Saab | Aug 1994 | A |
5342386 | Trotta | Aug 1994 | A |
5342387 | Summers | Aug 1994 | A |
5346467 | Coll | Sep 1994 | A |
5346471 | Raulerson | Sep 1994 | A |
5348536 | Young et al. | Sep 1994 | A |
5354263 | Coll | Oct 1994 | A |
5354309 | Schnepp-Pesch et al. | Oct 1994 | A |
5356423 | Tihon et al. | Oct 1994 | A |
5356424 | Buzerak et al. | Oct 1994 | A |
5358689 | Jones et al. | Oct 1994 | A |
5360397 | Pinchuk | Nov 1994 | A |
5364340 | Coll | Nov 1994 | A |
5364344 | Beattie et al. | Nov 1994 | A |
5366464 | Belknap | Nov 1994 | A |
5372600 | Beyar et al. | Dec 1994 | A |
5374245 | Marhurkar | Dec 1994 | A |
5378230 | Marhurkar | Jan 1995 | A |
5380270 | Ahmadzadeh | Jan 1995 | A |
5380276 | Miller et al. | Jan 1995 | A |
5383928 | Scott et al. | Jan 1995 | A |
5391196 | Devonec | Feb 1995 | A |
5395316 | Martin | Mar 1995 | A |
5399172 | Martin et al. | Mar 1995 | A |
5401257 | Chevalier, Jr. et al. | Mar 1995 | A |
5403291 | Abrahamson | Apr 1995 | A |
5405320 | Twardowski et al. | Apr 1995 | A |
5405329 | Durand | Apr 1995 | A |
5405341 | Martin | Apr 1995 | A |
5405380 | Gianotti et al. | Apr 1995 | A |
5411490 | Tennican et al. | May 1995 | A |
5440327 | Stevens | Aug 1995 | A |
5445624 | Jimenez | Aug 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5451206 | Young | Sep 1995 | A |
5464398 | Haindl | Nov 1995 | A |
5470322 | Horzewski et al. | Nov 1995 | A |
5472417 | Martin et al. | Dec 1995 | A |
5472432 | Martin | Dec 1995 | A |
5472435 | Sutton | Dec 1995 | A |
5480380 | Martin | Jan 1996 | A |
5484424 | Cottenceau et al. | Jan 1996 | A |
5486159 | Maharkur | Jan 1996 | A |
5489278 | Abrahamson | Feb 1996 | A |
5509897 | Twardowski et al. | Apr 1996 | A |
5514100 | Marhurkar | May 1996 | A |
5514176 | Bosley, Jr. | May 1996 | A |
5514178 | Torchio | May 1996 | A |
5520697 | Lindenberg et al. | May 1996 | A |
5522807 | Luther | Jun 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5531741 | Barbacci | Jul 1996 | A |
5533985 | Wang | Jul 1996 | A |
5540713 | Schnepp-Pesch et al. | Jul 1996 | A |
5542937 | Chee et al. | Aug 1996 | A |
5553665 | Gentry | Sep 1996 | A |
5554136 | Luther | Sep 1996 | A |
5556390 | Hicks | Sep 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5569182 | Twardowski et al. | Oct 1996 | A |
5569184 | Crocker et al. | Oct 1996 | A |
5569195 | Saab | Oct 1996 | A |
5569215 | Crocker | Oct 1996 | A |
5569218 | Berg | Oct 1996 | A |
5571093 | Cruz et al. | Nov 1996 | A |
5573508 | Thornton | Nov 1996 | A |
5599291 | Balbierz et al. | Feb 1997 | A |
5601538 | Deem | Feb 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5622665 | Wang | Apr 1997 | A |
5624413 | Markel et al. | Apr 1997 | A |
5630794 | Lax et al. | May 1997 | A |
5632734 | Galel et al. | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5643222 | Marhurkar | Jul 1997 | A |
5647843 | Mesrobian et al. | Jul 1997 | A |
5649909 | Cornelius | Jul 1997 | A |
5653689 | Buelna et al. | Aug 1997 | A |
5658263 | Dang et al. | Aug 1997 | A |
5667486 | Mikulich et al. | Sep 1997 | A |
5674277 | Freitag | Oct 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5681274 | Perkins et al. | Oct 1997 | A |
5683640 | Miller et al. | Nov 1997 | A |
5685862 | Marhurkar | Nov 1997 | A |
5685867 | Twardowski et al. | Nov 1997 | A |
5695479 | Jagpal | Dec 1997 | A |
5695482 | Kaldany | Dec 1997 | A |
5695789 | Harris | Dec 1997 | A |
5707386 | Schnepp-Pesch et al. | Jan 1998 | A |
5709874 | Hanson et al. | Jan 1998 | A |
5718862 | Thompson | Feb 1998 | A |
5725814 | Harris | Mar 1998 | A |
5730733 | Mortier et al. | Mar 1998 | A |
5755774 | Pinchuk | May 1998 | A |
5762630 | Bley et al. | Jun 1998 | A |
5766209 | Devonec | Jun 1998 | A |
5769868 | Yock | Jun 1998 | A |
5772641 | Wilson | Jun 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5791036 | Goodin et al. | Aug 1998 | A |
5792105 | Lin et al. | Aug 1998 | A |
5792124 | Horrigan et al. | Aug 1998 | A |
5792400 | Talja et al. | Aug 1998 | A |
5795319 | Ali | Aug 1998 | A |
5795326 | Simán | Aug 1998 | A |
5830179 | Mikus et al. | Nov 1998 | A |
5830184 | Basta | Nov 1998 | A |
5830196 | Hicks | Nov 1998 | A |
5836925 | Soltesz | Nov 1998 | A |
5843028 | Weaver et al. | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5851203 | van Muiden | Dec 1998 | A |
5860999 | Schnepp-Pesch et al. | Jan 1999 | A |
5865815 | Tihon | Feb 1999 | A |
5876417 | Devonec et al. | Mar 1999 | A |
5895378 | Nita | Apr 1999 | A |
5897537 | Berg et al. | Apr 1999 | A |
5899891 | Racz | May 1999 | A |
5899892 | Mortier et al. | May 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5911715 | Berg et al. | Jun 1999 | A |
5928217 | Mikus et al. | Jul 1999 | A |
5947939 | Mortier et al. | Sep 1999 | A |
5961511 | Mortier et al. | Oct 1999 | A |
5964744 | Balbierz et al. | Oct 1999 | A |
5964771 | Beyar et al. | Oct 1999 | A |
5976120 | Chow et al. | Nov 1999 | A |
5980505 | Wilson | Nov 1999 | A |
5984907 | McGee et al. | Nov 1999 | A |
6007478 | Siess et al. | Dec 1999 | A |
6019789 | Dinh et al. | Feb 2000 | A |
6033413 | Mikus et al. | Mar 2000 | A |
6135992 | Wang | Oct 2000 | A |
6139536 | Mikus et al. | Oct 2000 | A |
6620202 | Bottcher et al. | Sep 2003 | B2 |
6719804 | St. Pierre | Apr 2004 | B2 |
7291180 | St. Pierre | Nov 2007 | B2 |
20020143389 | St. Pierre | Oct 2002 | A1 |
Number | Date | Country |
---|---|---|
1092927 | Jan 1981 | CA |
1150122 | Jul 1983 | CA |
1167727 | May 1984 | CA |
1193508 | Sep 1985 | CA |
1219785 | Mar 1987 | CA |
1225299 | Nov 1987 | CA |
2259865 | Jun 1974 | DE |
3112762 | Jan 1983 | DE |
35 17 813 | Nov 1986 | DE |
37 40 288 | Apr 1989 | DE |
41 03 573 | Aug 1992 | DE |
41 34 030 | Apr 1993 | DE |
93 14 585.3 | Jan 1994 | DE |
0036642 | Sep 1981 | EP |
0079719 | May 1983 | EP |
0101890 | Mar 1984 | EP |
0101890 | Mar 1984 | EP |
0144525 | Jun 1985 | EP |
0168136 | Jan 1986 | EP |
0183421 | Jun 1986 | EP |
0 326 908 | Aug 1989 | EP |
0333308 | Sep 1989 | EP |
0183421 | Apr 1990 | EP |
0386408 | Sep 1990 | EP |
0490459 | Jun 1992 | EP |
0490459 | Jun 1992 | EP |
0554722 | Aug 1993 | EP |
0 876 803 | Nov 1998 | EP |
0 916 362 | May 1999 | EP |
1285953 | Jan 1962 | FR |
1508959 | Dec 1967 | FR |
2297640 | Aug 1976 | FR |
2530958 | Feb 1984 | FR |
2 611 486 | Sep 1988 | FR |
2017499 | Oct 1979 | GB |
2156220 | Oct 1985 | GB |
2235384 | Mar 1991 | GB |
57-90150 | Jun 1982 | JP |
62-20830 | Jan 1987 | JP |
WO 8404043 | Oct 1984 | WO |
WO 9526763 | Oct 1995 | WO |
WO 9528982 | Nov 1995 | WO |
WO 9529051 | Nov 1995 | WO |
WO 9535130 | Dec 1995 | WO |
WO 9710858 | Mar 1997 | WO |
WO 9717094 | May 1997 | WO |
WO 9737699 | Oct 1997 | WO |
WO 9737718 | Oct 1997 | WO |
WO 9739788 | Oct 1997 | WO |
WO 9822159 | May 1998 | WO |
WO 9843695 | Oct 1998 | WO |
WO 9856313 | Dec 1998 | WO |
WO 9939661 | Aug 1999 | WO |
WO 9949811 | Oct 1999 | WO |
WO 02078778 | Oct 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20080086215 A1 | Apr 2008 | US |
Number | Date | Country | |
---|---|---|---|
60280809 | Apr 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10765382 | Jan 2004 | US |
Child | 11935179 | US | |
Parent | 10032712 | Oct 2001 | US |
Child | 10765382 | US |